论文部分内容阅读
泊马度胺是第三代的免疫调节剂,具有直接杀伤肿瘤细胞、免疫调节及抑制血管新生等作用~([1])。已经在欧盟及美国获批用于至少经过2种方案治疗后复发难治多发性骨髓瘤(relapse refractory multiple myeloma,RRMM)患者,这些治疗方案中应含有硼替佐米以及来那度胺,且对末次治疗无效。泊马度胺也即将成为在中国获批的第二个免疫调节剂,将用于多发性骨髓瘤(Multiple myeloma,MM)的治疗,在
Parmatide is the third generation of immunomodulatory agents, with direct killing of tumor cells, immune regulation and inhibition of angiogenesis and so on ~ ([1]). Patients who have been approved in the European Union and the United States for relapsed refractory multiple myeloma (RRMM) after treatment with at least two regimens should include bortezomib and lenalidomide The last treatment is invalid. Pomalidomide is also about to become the second immunomodulator approved in China to be used in the treatment of multiple myeloma (MM)